Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma

Benjamin Chuah, Robert Lim, Michael Boyer, Ai Bee Ong, Seng Weng Wong, Hwai Loong Kong, Michael Millward, Stephen Clarke, Boon Cher Goh

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is a hypervascular tumour, which overexpresses vascular endothelial growth factor. Thalidomide is an antiangiogenic agent with activity in refractory multiple myeloma. The purpose of this multi-centre phase II study was to evaluate the efficacy and toxicity of thalidomide in patients with advanced HCC. From February 2000 to November 2001, 37 patients with histologically proven, bi-dimensionally measurable advanced, unresectable HCC were enrolled. The starting dose of Thalidomide was 100 mg per day and escalated weekly by 100 mg to a maximum dose of 800 mg/day according to individual patient tolerance. Radiological tumour response and treatment related toxicities were prospectively assessed. Thirty-seven patients were evaluable for toxicity and 24 patients were evaluable for response. The median Thalidomide dose was 400 mg/day. There was no complete response (CR). One patient had a radiological partial response (PR) (3%; 95% confidence interval [95% CI], 0% to 8%) and six (16%) patients had stable disease for more than 6 months. Somnolence and fatigue were the most common side effects, occurring in 84% and 73% of patients respectively. Thalidomide monotherapy is tolerable and associated with modest antitumour activity in advanced HCC.

Original languageEnglish
Pages (from-to)234-238
Number of pages5
JournalActa Oncologica
Volume46
Issue number2
DOIs
Publication statusPublished - 23 Feb 2007
Externally publishedYes

Fingerprint Dive into the research topics of 'Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Chuah, B., Lim, R., Boyer, M., Ong, A. B., Wong, S. W., Kong, H. L., Millward, M., Clarke, S., & Goh, B. C. (2007). Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncologica, 46(2), 234-238. https://doi.org/10.1080/02841860600702076